ClinConnect ClinConnect Logo
Search / Trial NCT00677560

The Natural History of Small Airways Physiology in Diseased and Healthy States

Launched by IMPERIAL COLLEGE LONDON · May 13, 2008

Trial Information

Current as of October 21, 2025

Completed

Keywords

Resistance Reactance Inflammation Lung Function Respiratory Function

ClinConnect Summary

Background

The main objective of this study is to measure the damage of the small airways in lung disease exploring the "silent zone" with methods that have not been used before together in the same patients. Furthermore, because this is a 4 year longitudinal study, the study team will investigate the time related changes of small airway function in lung disease and normal healthy subjects.

The study will also investigate the relationship between small airway resistance and inflammation.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • male or female, aged between 18-85 years;
  • volunteers who are able to give written informed consent Patients meeting the diagnostic criteria for asthma, COPD, ILD, CF, chronic cough.
  • Exclusion Criteria:
  • upper respiratory tract infection within the previous 28 days
  • any history or evidence of renal, cardiovascular, gastrointestinal or hepatic disease
  • any history and evidence of neuropsychiatric disease
  • treatment with antibiotics within 4 weeks prior to the study
  • alcohol, drug abuse or any other condition associated with poor compliance
  • breast feeding
  • pregnancy
  • are unable to provide written informed consent

About Imperial College London

Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.

Locations

London, United Kingdom

Patients applied

0 patients applied

Trial Officials

Paolo Paredi, MD, PhD

Study Director

Airway Disease Section, National Heart and Lung Institute, Imperial College, London

Omar A Usmani, MD, PhD

Principal Investigator

Airway Disease Section, National Heart and Lung Institute, Imperial College, London

Peter J Barnes, Prof

Study Chair

Airway Disease Section, National Heart and Lung Institute, Imperial College, London

Neil Pride, Prof

Study Chair

Airway Disease Section, National Heart and Lung Institute, Imperial College, London

Michael Goldman, Prof

Study Chair

Airway Disease Section, National Heart and Lung Institute, Imperial College, London

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials